Patients with Lung Cancer who had Exhausted All Other Treatment Options Achieved Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Docetaxel EDINBURGH, United Kingdom, (GLOBE ...

esmo group (esmo), a leading global full-service systems integrator, developer, and supplier of innovative and advanced automation solutions, is proud to announce the launch of its latest product—the ...

in patients with muscle-invasive bladder cancer (MIBC), according to findings from the phase 3 NIAGARA study presented at the ...

The 18-team field is set for the 2024 edition of the MLS Cup Playoffs. After setting a league record for the most points scored in a single season, Inter Miami CF was eliminated in the first round ...

Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial ...

Check out some anticipated series in the video above or the slideshow gallery below, followed by the full list of new Fall season 2024 anime and where to watch them in the U.S. and their ...

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

ECHO, a proprietary diagnostic for detection of ecDNA amplified oncogenes In September, analytical validation data was presented at the European Society for Medical Oncology (ESMO) Congress for the ...

About Aptevo Therapeutics Inc. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for the treatment of cancer. Aptevo is seeking ...

Investigators report findings from a phase 3 trial demonstrating that transdermal estradiol patches were as effective as luteinizing hormone-releasing hormone agonists.

GAITHERSBURG, Md., US, 06 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative ...